Moderna’s information in children ages 12-17 “in line with a vaccine efficacy of 100%”

Extreme close-up photo of a gloved hand holding a tiny jar.

Enlarge / A vial of the present Moderna COVID-19 vaccine. (credit score: Getty | Ivan Romano)

Moderna’s COVID-19 vaccine seems secure and extremely efficient in adolescents ages 12 to 17, in response to the top-line outcomes of a small scientific trial the corporate introduced Tuesday.

The corporate plans to submit the trial information to the US Meals and Drug Administration early subsequent month, searching for authorization for expanded use within the age group.

If the FDA grants the authorization, Moderna’s vaccine would be the second COVID-19 vaccine out there to be used in children as younger as 12 within the US. Earlier this month, the FDA approved the Pfizer-BioNTech vaccine to be used in adolescents ages 12 to 15. (The Pfizer-BioNTech vaccine was initially approved to be used in individuals ages 16 and up, whereas Moderna’s was initially approved to be used in individuals ages 18 and up.)

Learn 5 remaining paragraphs | Feedback

Related Posts

Leave a Reply

Your email address will not be published.